1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines.

Slides:

Advertisements

Similar presentations

Pharmacovigilance Shanthi Pal, M.Pharmacy, PhD

Advertisements

1 WHO Programme for International Drug Monitoring : ensuring the safety of medicines Dr Mary Couper & Dr Shanthi Pal Quality Assurance and Safety: Medicines.

WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.

World Health Organization

1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.

WHOs Normative Work in the Field of Pharmaceuticals - introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines Essential.

Strategies for Working with Countries – Regional and Sub-Regional Perspective and Experiences Essential Drugs and Medicines Policy WHO South-East Asia.

Addressing the innovation gap: strategies to inform treatment policies in low and middle income countries Shanthi Pal, WHO, Switzerland Sten Olsson, Uppsala.

COUNTRY ACTION PLAN for INTRODUCING AND IMPLEMENTING A PHARMACOVIGILANCE PROGRAMME IN KENYA Dorine Kagai and Wilfred Oguta Pretoria,2004.

Safety and Vigilance (SAV)

The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January

1 | MedInfo Copenhagen - | August 21, 2013 Profile of Normative Work and Global eHealth Activities WHO Headquarters Dr. Ramesh S. Krishnamurthy.

A STRONG PATIENTS’ VOICE TO DRIVE BETTER HEALTH IN EUROPE EPF Annual General Meeting 19 May 2010 EPF Annual General Meeting 19 May 2010.

Africa Herbal Antimalaria Meeting Nairobi, March 2006 Research on Traditional Medicines used for the Treatment of Malaria in WHO African Region Traditional.

PUBLIC HEALTH PROGRAMMES & PHARMACOVIGILANCE Shanthi Pal Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies World.

Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.

Isah, Ambrose Ohumagho (1); Pal, Shanthi (2); Olsson, Sten (3)

1 Establishing a Pharmacovigilance Centre Sten Olsson the Uppsala Monitoring Centre.

WHO European Centre for Environment and Health, Rome In collaboration with the Kazakhstan School Public Health Seminar on Food Law Almaty October.

Nadja Jastrebova Pharmacovigilance Consulting Global Services Section

ARN14 Feb JSPS visit Showa University National “prescribing rule”;  Newly prescribed drugs is provided for not more than 2 weeks  Long term medications.

Atlanta meeting Getting it done for maternal and new born health PwC: A partner in development 20 January

The South African perspective

Pharmacovigilance in Kenya Dr. Dorine Kagai (NASCOP) Mr. George Muthuri (PPB) Ministry of Medical Services 23 nd November, 2009 ARV PV TRAINING TZ.

Pharmacovigilance Programme of India

P HARMACOVIGILANCE IN P UBLIC H EALTH P ROGRAMME Dr.Sumedh M.Gaikwad MD,DM Clinical Pharmacology, Director Medical Services, Richter Themis Medicare Ltd.

MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.

IAEA International Atomic Energy Agency PGEC Part IV The International System of Radiation Protection and the Regulatory Framework Module IV 2 Conceptual.

Sten Olsson WHO Programme Expert Uppsala Monitoring Centre Sweden

A project implemented by the HTSPE consortium This project is funded by the European Union SECURITY AND CITIZENS SECURITY AND CITIZENSHIP CONSUMER

Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.

1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:

© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.

EUnetHTA Joint Action 2010–2012 | EUnetHTA Joint action Sharing expertise and efforts Iris Pasternack, research officer, FINOHTA.

Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO

Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.

Pharmacovigilance: challenges facing WHO Shanthi Pal Leader, Medicines Safety Safety and Vigilance, WHO, Geneva.

Drug Information Services. Aims of the Course To introduce the students how to locate, evaluate drug information’s systematically, manage and distribute.

Challenges for the WHO Programme for International Drug Monitoring Mary Couper, Shanthi Pal, Mitsuko Imai, Maria Cuadrillero, Ana Garcia.

Dr Mary Couper Quality Assurance and Safety of Medicines WHO

Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.

TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.

Minimum requirements for Pharmacovigilance in countries.

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.

Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.

VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.

1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.

EDM Strategy for Working with Countries: the Uganda Example

Efficacy and Safety of Medicines

WHO’s policy priorities and projects

Overview of the EAC Pharmacovigilance and Post-Marketing Surveillance Systems 1ST International High Level Multi-Stakeholder Conference Nairobi, 2-4.

پنل نگاهی به جایگاه ایران در صادرات گیاهان دارویی، فرآورده های طبیعی و سنتی و بررسی مسائل و چالش های آن دکتر بی بی مهشید حایری زاده معاون اداره کل نظارت.

WHO Programme for International Drug Monitoring

Strengthening systems for safety monitoring for SMC in the Sahel

Quality Assurance and Safety of Medicines

Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.

Pharmacovigilance in Uganda

Helen Lee, European Commission

Medicines safety in WHO: promoting best practices in Pharmacovigilance

Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.

4.2 CLIMATE SERVICES, ACTION AND RESILIENCE

Christine Halleux, MD, PhD

Medicines Safety Mary R. Couper

WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:

Aspects of pharmacovigilance: Development Safety Update Report (DSUR)

Quality Assurance and Safety of Medicines

Эмийн гаж нөлөөг бүртгэн мэдээлэх, ач холбогдол

Pharmacovigilance.

Presentation transcript:

1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines World Health Organization

2 Birth of modern pharmacovigilance Thalidomide – Phocomelia 1961

3 16th World Health Assembly 1963 Assembly Resolution Clinical and Pharmacological Evaluation of Drugs INVITES Member States to arrange for a systematic collection of information on serious adverse drug reactions observed during the development of a drug and, in particular, after its release for general use.

4 WHO Programme for International Drug Monitoring HQ-WHO + 6 Regional offices WHOCollaborating Centre, Uppsala NationalCentres HIV/AIDS MPS Malaria TDR Others

5 Advisory Committee on Safety of Medicinal Products (ACSoMP) The Advisory Committee on Safety of Medicinal Products shall provide advice on pharmacovigilance policy and issues related to the safety and effectiveness of medicinal products to the relevant Assistant Director-General in WHO and through him / her – to the Collaborating Centre for International Drug Monitoring (the Uppsala Monitoring Centre), and – to the Member States of WHO.

6 Pharmacovigilance in WHO HQ 1. Exchange of Information 2. Policies, guidelines, normative activities 3. Country support 4. Collaborations 5. Resource mobilisation

7 1. Exchange of Information National Information Officers Publications (WHO Pharm Newsletter, Restricted Pharm List, Drug Alerts, WHO Drug Information) International Conference of Drug Regulatory Authorities (ICDRA)

8 2. Policies, Guidelines and Normative Activities Guidelines – The Importance of Pharmacovigilance (2002) – Safety Reporting - A guide to detecting and reporting adverse drug reactions (2002) – Policy perspectives on medicines (Pharmacovigilance) 2004 – Safety monitoring of herbal medicines (2004) – Pharmacovigilance in Public Health – Advisory Committee for the Safe Use of Medicinal Products (ACSoMP)

9 3. Country support Training courses on pharmacovigilance (Regional Training Courses, biennial course by UMC and HQ) Address specific / stated needs: kava, ARVs, antimlalarials…. Annual Meeting of Pharmacovigilance Centres 10 courses offered in 2008

10 4. Collaborations & Partnerships within WHO Malaria HIV/AIDS Leprosy Lymphatic Filariasis Leishmaniasis Chagas Patient Safety Poisons and Chemicals Safety Traditional Medicines Vaccines Over a 100 million people targeted for either diethylcarbamazine citrate (DEC) plus albendazole or ivermectin plus albendazole.

11 5. Resource Mobilisation Gates foundation European commission Global Fund Others Human resources: PvSF